

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
In vitro generation of cancer stem cells (CSCs) and selection based on fucosyltransferase 4 α 1,3-fucosyltransferase myeloid-specific (FUT4; CD15; SSEA-1)	Differentiation of CSCs from somatic cells could help identify new markers and therapeutics for cancer. CSCs were generated by expression of human telomerase reverse transcriptase (hTERT), H-RasV12, simian virus 40 large T (SV40 LT) and small T (SV40 ST) antigens in human fibroblasts and purified based on <i>SSEA-1</i> expression. In culture, the CSCs differentiated into heterogeneous cell types and were able to self-renew. Next steps include using the <i>in vitro</i> -generated CSCs to identify new CSC-specific markers and therapeutic targets.	Findings unpatented; unavailable for licensing	Scaffidi, P. & Misteli, T. <i>Nat. Cell</i> <i>Biol.</i> ; published online Aug. 21, 2011; doi:10.1038/ncb2308 Contact: Paola Scaffidi, National Cancer Institute, Bethesda, Md. e-mail: scaffidp@mail.nih.gov
	<i>SciBX</i> 4(35); doi:10.1038/scibx.2011.1000 Published online Sept. 8, 2011		

SciBX: Science–Business eXchange